Gilead Sciences, Inc. (GILD) EVP Gregg H. Alton Sells 25,000 Shares
Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.93% during midday trading on Wednesday, reaching $82.42. 6,711,405 shares of the company were exchanged. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The stock has a market capitalization of $107.63 billion, a price-to-earnings ratio of 8.95 and a beta of 1.14. The firm’s 50-day moving average price is $80.40 and its 200 day moving average price is $71.48.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.08 EPS. Equities analysts predict that Gilead Sciences, Inc. will post $8.78 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a $0.52 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.52%. Gilead Sciences’s dividend payout ratio is 22.58%.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) EVP Gregg H. Alton Sells 25,000 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/04/gilead-sciences-inc-gild-evp-gregg-h-alton-sells-25000-shares-2.html.
Several analysts have recently commented on the stock. Bank of America Corporation reduced their target price on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday. Jefferies Group LLC restated a “hold” rating and issued a $93.00 target price on shares of Gilead Sciences in a research note on Wednesday. Mizuho restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Leerink Swann restated a “market perform” rating and issued a $87.00 target price (up previously from $82.00) on shares of Gilead Sciences in a research note on Wednesday, September 20th. Finally, Royal Bank Of Canada initiated coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They issued an “outperform” rating and a $94.00 price objective for the company. Eleven research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $85.36.
Several institutional investors and hedge funds have recently modified their holdings of GILD. Parnassus Investments CA increased its holdings in shares of Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after purchasing an additional 4,556,901 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after purchasing an additional 2,727,063 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Gilead Sciences by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after purchasing an additional 2,700,600 shares during the period. Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Gilead Sciences by 50.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock valued at $438,244,000 after purchasing an additional 2,062,886 shares during the period. Institutional investors own 73.99% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.